Conversion to Complete, Parenchyma-Sparing Resection after Prolonged Denosumab for Bilateral Multifocal Pulmonary Metastases from Giant Cell Tumor of Bone: A Case Report. [PDF]
Ann Thorac Cardiovasc SurgOmura S, Sasaki A, Anazawa U, Eguchi K.
europepmc +1 more source
Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors: Incremental Benefit, Debatable Value [PDF]
, 2011 Howard West
openalex +1 more source
Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation. [PDF]
Sci RepCho YH, Byun SE, Lee HH.
europepmc +1 more source
Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database. [PDF]
Front Endocrinol (Lausanne)Bai H +5 more
europepmc +1 more source
Denosumab: riesgo de osteonecrosis mandibular e hipocalcemia
, 2014 Aemps Agencia Española de Medicamentos y Productos Sanitarios
openalex +1 more source
Adherence to denosumab therapy and all-cause mortality in dialysis patients with osteoporosis: a retrospective cohort exploratory study. [PDF]
Front PharmacolChen YC +4 more
europepmc +1 more source
Denosumab (Prolia): new option in the prevention of fractures [PDF]
, 2010 Steve Chaplin, Juliet Compston
openalex +1 more source
Review of: "Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients" [PDF]
Nazım Can Demircan
openalex +1 more source